AP NEWS

ImpediMed Highlights Publication of Recommendations in New England Journal of Medicine: Supports Use of Bioimpedence and L-Dex Measurement for Lymphedema Assessment

December 4, 2018

BRISBANE, Australia & CARLSBAD, Calif.--(BUSINESS WIRE)--Dec 4, 2018--ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), highlights the recent publication of a case vignette entitled, “Lymphedema after Breast Cancer Treatment,” published in the (NEJM), authored by the internationally recognized authority on lymphedema, Stanley G. Rockson, M.D., Allan and Tina Neill Professor of Lymphatic Research and Medicine, Stanford University. Dr. Rockson advocates placing patients in a surveillance program that uses quarterly assessments using BIS during the first year after treatment when the majority of lymphedema cases appear.

Highlighting lymphedema as a common clinical problem, providing evidence to support recommendations and reviewing formal guidelines, Dr. Rockson also calls for prompt use of compression garments, and, as necessary, use of decongestive physiotherapy for symptoms or for worrisome changes in bioimpedance.

This article follows another recently published editorial by Dr. Rockson in Lymphatic Research and Biology (LRB) where he serves as the editor-in-chief. In this piece, he focuses on the first 12 months of the PREVENT trial, which recommended a strict protocol using BIS in surveillance of cancer survivors in early detection of lymphedema.

Richard Carreon, managing director and CEO, ImpediMed, says, “Dr. Rockson’s message is significant and clear: BIS is the recommended protocol in surveillance of cancer survivors. This high-profile, independent review continues to build the clinical evidence for the use of BIS in the early detection of lymphedema and its association with better outcomes.”

Carreon emphasizes that these recommendations, coupled with the other recently announced independent L-Dex studies, will have a strong and positive impact on value-based reimbursement from the nation’s payers for ImpediMed technology.

About ImpediMed

Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO ® for multiple indications, including heart failure and lymphedema, sold in select markets globally. Visit www.impedimed.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181204005160/en/

CONTACT: Media:

Laura Carabello

lcarabello@cpronline.com

201.641.1911 x12

KEYWORD: AUSTRALIA UNITED STATES NORTH AMERICA AUSTRALIA/OCEANIA CALIFORNIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES ONCOLOGY RESEARCH MEDICAL SUPPLIES SCIENCE

SOURCE: ImpediMed Limited

Copyright Business Wire 2018.

PUB: 12/04/2018 09:00 AM/DISC: 12/04/2018 09:00 AM

http://www.businesswire.com/news/home/20181204005160/en

AP RADIO
Update hourly